# Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)

> **NCT00423150** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 86 (actual)

## Conditions studied

- Colorectal Neoplasm
- Head and Neck Neoplasm
- Carcinoma, Non-Small-Cell Lung
- Esophageal Neoplasm

## Interventions

- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00423150
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01-26
- **Primary completion:** 2009-06-11
- **Final completion:** 2009-06-11
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2017-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00423150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00423150, "Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00423150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*